CAMBRIDGE, Mass.--(BUSINESS WIRE)--Neurovance, Inc. today announced that its Phase 2b trial of centanafadine SR (CTN), a non-stimulant for the treatment of adults with ADHD, met both the primary and ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Neurovance, Inc. today announced acceptance of its Investigational New Drug (IND) application for EB-1020 SR by the US Food and Drug Administration and initiation of ...

—EB-1020 SR Is a Non-Stimulant but with the Potential Efficacy Profile of a Stimulant for Adult Attention Deficit Hyperactivity Disorder (ADHD)— CAMBRIDGE, Mass.--Neurovance, Inc. today announced that ...

Data presented at Society of Biological Psychiatry 69th Annual Scientific Meeting; lays groundwork for EB-1020 SR as a potential treatment option for adult ADHD Neurovance, Inc. today announced ...

Neurovance has now raised a total of $20 million for its abuse-proof drug for adult attention deficit-hyperactivity disorder. Neurovance has raised another $5.5 million for its abuse-proof drug for ...

Neurovance Closes $7M Series A1 Round for Development of EB-1020 for ADHD; Reports Phase 1 Clinical Trial Results Neurovance, Inc. today announced that it has closed a $7 million series A1 round led ...

Cambridge biotech Neurovance Inc. came out of stealth mode Thursday with $7 million in Series A1 funding to develop a new, non-addictive drug to treat Attention deficit-hyperactivity disorder (ADHD).

Otsuka Pharmaceutical will pay $100 million up front and up to $150 million in potential milestone payments to acquire Cambridge, Mass.-based Neurovance, a six-year ...

Cambridge-based company Neurovance said today it has received $7.1 million in Series A1 funding to further advance development of EB-1020, a drug designed to treat adult attention deficit ...

Otsuka Pharmaceutical Co. will pay about $100 million to acquire Neurovance Inc. and could make additional payments based on the venture-backed drug company’s development and sales performance, the ...